Blount International Inc. (BLT) Financials Nov 14, 2014,

New Post Public Reply Private Reply Replies (0) Message Board
Hirata
Blount International Inc. (BLT) Financials Nov 14, 2014, 4:28 p.m.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Blount International Inc.


Fiscal year is January-December. All values USD millions. 2009 2010 2011 2012 2013 5-year trend
Sales/Revenue 502.43M 611.48M 831.63M 927.67M 900.6M
Cost of Goods Sold (COGS) incl. D&A 332.93M 407.45M 576.61M 670.38M 641.18M
COGS excluding D&A 306.99M 379.86M 541.81M 625.26M 591.66M
Depreciation & Amortization Expense 25.94M 27.6M 34.8M 45.12M 49.52M
Depreciation 20.4M 20.97M 23.48M 28.59M 33.48M
Amortization of Intangibles 5.55M 6.63M 11.32M 16.53M 16.04M
Gross Income 169.5M 204.03M 255.02M 257.29M 259.42M
2009 2010 2011 2012 2013 5-year trend
SG&A Expense 109.12M 118.47M 153.76M 170.54M 173.52M
Research & Development 8.5M 11M 19.6M 17M 15.2M
Other SG&A 100.62M 107.47M 134.16M 153.54M 158.32M
Other Operating Expense 0 0 0 0 0
Unusual Expense 6.89M 7M 3.31M 7.48M 47.88M
EBIT after Unusual Expense (6.89M) (7M) (3.31M) (7.48M) (47.88M)
Non Operating Income/Expense 2.94M (427,000) (4.45M) (284,000) (2.62M)
Non-Operating Interest Income 206,000 119,000 171,000 158,000 630,000
Equity in Affiliates (Pretax) 0 0 0 0 0
Interest Expense 24.71M 25.64M 18.72M 17.36M 18.47M
Gross Interest Expense 24.71M 25.64M 18.72M 17.86M 18.67M
Interest Capitalized - - - 500,000 200,000
Pretax Income 31.93M 52.61M 74.95M 61.79M 17.56M
Income Tax 8.94M 11.21M 25.27M 22.2M 12.72M
Income Tax - Current Domestic 2.53M 2.63M 17.37M 17.47M 9.09M
Income Tax - Current Foreign 4.27M 4.52M 5.57M 12.33M 9.32M
Income Tax - Deferred Domestic 2.35M 3.29M 906,000 (7.18M) (6.52M)
Income Tax - Deferred Foreign (201,000) 768,000 1.43M (409,000) 833,000
Income Tax Credits 0 0 0 0 0
Equity in Affiliates 0 0 0 0 0
Other After Tax Income (Expense) - - - 0 0
Consolidated Net Income 22.99M 41.4M 49.68M 39.59M 4.84M
Minority Interest Expense 0 0 0 0 0
Net Income 22.99M 41.4M 49.68M 39.59M 4.84M
Extraordinaries & Discontinued Operations 0 5.8M 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg - 0 0 0 0
Discontinued Operations 0 5.8M 0 0 0
Net Income After Extraordinaries 22.99M 47.2M 49.68M 39.59M 4.84M
Preferred Dividends 0 0 0 0 0
Net Income Available to Common 22.99M 41.4M 49.68M 39.59M 4.84M
EPS (Basic) 0.48 0.99 1.02 0.81 0.10
Basic Shares Outstanding 47.76M 47.92M 48.7M 49.17M 49.48M
EPS (Diluted) 0.48 0.97 1.01 0.79 0.10
Diluted Shares Outstanding 48.27M 48.51M 49.43M 49.9M 50.12M
EBITDA 86.32M 113.15M 136.06M 131.87M 135.42M
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

M&A Source's 2026 Conference Tackles Deal-Making Drama

Updated Category News Views 130

High Stakes and Deep Insights Await in Houston Cracking the nut of lower-middle market transactions ain’t a walk in the park. M&A Source®'s Fall 2026 Conference is gearing up to address the very dramas that lurk behind the scenes. Kicking off November 2-4 at the opulent JW Marriott in Houston, Texas, the event is looking to assemble a heavyweight lineup of...

Continue Reading
Endava Faces Class Action: Investors Eye Their Next Move

Updated Category News Views 0

A Mess That Investors Can't Ignore If you're holding onto Endava plc shares, you've probably felt that gut-punch lately. Yeah, things are getting heated with a class action lawsuit alleging the company played fast and loose with its accounting practices. The complaint's about some shady dealings that may have thrown off investors' perceptions. The Core Allegations This...

Continue Reading
Astellas and Audax Forge $1.34B Immuno-Oncology Deal

Updated Category News Views 36

Big Moves in Immuno-Oncology: Astellas' Latest Bet You hear 'immuno-oncology,' you think breakthrough, right? Well, friends, that's what Astellas and Audax Biosciences are shooting for with their fresh handshake over DAX-044. On October 27, 2026, in Tokyo and Melbourne, the two outfits announced they're joining forces to bring this novel immunotherapy to the table. It's...

Continue Reading
OneQode & AdaniConneX Forge AI Path in India

Updated Category News Views 17

A Major Step Forward in AI Infrastructure When two heavyweights clash, you better believe folks are paying attention. OneQode’s deal with AdaniConneX is like a shot across the bow in the AI infrastructure arena. They’re not just dipping a toe in India’s tech waters; they’re diving headfirst with 14 MW of data center muscle right there in Siruseri Sipcot, Chennai....

Continue Reading
Lynk Pharmaceuticals' Zemprocitinib Shines in Phase III RA Trial

Updated Category News Views 48

A Deep Dive into Lynk Pharmaceuticals' Latest Revelation Lynk Pharmaceuticals just dropped a bombshell with their latest Phase III trial results for zemprocitinib. This selective JAK1 inhibitor seems to be bringing some serious game in the fight against moderate-to-severe rheumatoid arthritis (RA), especially for folks who haven't had much luck with biologics. The drug...

Continue Reading
Brightstar's Cash Pop Shakes Up Illinois Lottery Scene

Updated Category News Views 63

A New Twist in Illinois: Cash Pop's Arrival Here's something fresh off the press: the Illinois Lottery is now on the ride with Brightstar's Cash Pop. This patented game isn't just another number pick—it's an engaging draw-based game featuring hourly draws with price tags of $1, $2, $5, and $10. It's like clockwork, and trust me, it's more than just the usual spin....

Continue Reading
Etisalat Surges: Net Profit Soars 46% Amid Growth

Updated Category News Views 91

Etisalat's Stellar Performance: A Deeper Dive When a company like Etisalat drops news of a whopping 46% increase in net profit year-over-year, you sit up and pay attention. Those numbers aren’t just a flash in the pan; they're the result of some serious strategic maneuvers and ripe market conditions. Etisalat isn't resting on its laurels, and their latest financials...

Continue Reading
Amgen Declares Q4 Dividend Amidst Broad Horizons

Updated Category News Views 16

Amgen's Steady Dividend: A Testament to Stability Diving into the mess that is today's biotech market, Amgen (NASDAQ:AMGN) stands out like a beacon of stability with its recent dividend announcement. The Board's decision to dole out a $2.52 per share dividend for the fourth quarter of 2026 showcases confidence amidst both promising ventures and looming uncertainties....

Continue Reading
2026 World Laureates Forum Drives Science Forward

Updated Category News Views 78

A Meeting of Great Minds in Shanghai Alright, listen up. Shanghai's gearing up to be the nerve center for the 2026 World Laureates Forum (WLF), and it's seething with potential. This ain't your regular science fair; it's a lion's den of brainpower set to crack open the future of science and tech. With the heavy-hitters like Nobel and Turing laureates on the docket, you're...

Continue Reading
Mercado González Opens, Integrates Mexican Culture

Updated Category News Views 27

Dive into Mercado González's Cultural Opening Over in La Habra, Northgate González Market has just flung open the doors to its latest masterpiece: Mercado González. Picture this, a place where the mundanity of grocery shopping melds with a vibrant fiesta of Mexican cuisine, artisanry, and cultural vibes. They transformed an older store into something that commands not...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring Exelon's Earnings: Insights and Future Potential

Updated Category News Views 142

Understanding Exelon's Upcoming Earnings Report Exelon Corporation (NASDAQ: EXC) is preparing to reveal its quarterly earnings in the near future. Investors are keenly awaiting the results, as they want insights into the company’s performance and projections for the following period. Analysts predict that Exelon will report an earnings per share (EPS) of $0.39,...

Continue Reading
Vallourec Invites Warrant Holders to General Meeting

Updated Category News Views 157

Vallourec Invites Warrant Holders to General Meeting Vallourec has announced a significant upcoming event for its warrant holders, also known as BSA. This meeting is set to take place soon, providing an opportunity for holders to engage with the company's future decisions. Details of the Meeting The general meeting will occur at the Vallourec headquarters, where the...

Continue Reading
Investigation Initiated for Molina Healthcare Investors Following Financial Reports

Updated Category News Views 246

Pomerantz LLP Begins Investigation on Behalf of Molina Investors Pomerantz LLP has embarked on an investigation focusing on the interests of investors in Molina Healthcare, Inc. (NYSE: MOH). This inquiry aims to ascertain whether Molina and certain executives may have been involved in any unlawful activities related to securities fraud. Key Financial Findings and Investor...

Continue Reading
How SymphonyAI's Insights Drive E-commerce Growth in Grocery

Updated Category News Views 159

Unlocking E-commerce Potential in Grocery Retail In a transformative announcement, SymphonyAI, a leader in predictive and generative AI SaaS products for enterprises, has unveiled groundbreaking insights from its annual grocery e-commerce study. This research indicates a noteworthy 8% growth opportunity for retailers leveraging AI-driven strategies in their connected...

Continue Reading
Exploring the Impact of Honda and Nissan's Potential Merger

Updated Category News Views 408

Honda and Nissan's Strategic Talks Honda (NYSE:HMC) and Nissan (OTC:NSANY) have entered discussions that may lead to a potential merger, a significant move reflecting the shifting landscape of Japan's automotive industry. As these two giants explore deeper ties, it marks a notable strategy to face the competition posed by Tesla and various Chinese car manufacturers....

Continue Reading